Log In
Print this Print this

plinabulin (BPI-2358)

Also known as: NPI-2358

  Manage Alerts
Collapse Summary General Information
Company Nereus Pharmaceuticals Inc.
DescriptionHalimide-derived tumor vascular disrupting agent (VDA)
Molecular Target Tubulin
Mechanism of ActionMicrotubule depolymerization
Therapeutic Modality 
Latest Stage of DevelopmentPhase III
Standard IndicationNon-small cell lung cancer (NSCLC)
Indication DetailsSecond-line treatment of non-small cell lung cancer (NSCLC); Treat metastatic non-small cell lung cancer (NSCLC); Treat non-small cell lung cancer (NSCLC)
Regulatory Designation
PartnerBeyondSpring Pharmaceuticals Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today